Immediate placement of intrauterine device after second-trimester medical abortion-Secondary outcomes with one-year follow-up.

Acta Obstet Gynecol ScandJun 10, 2026 (epub)
Clinical ResearchObstetrics & GynecologyOpen access

Sara Hogmark, Caroline Westermark, Niklas Envall et al.

✦ AI-curated · Sources linked

In 30 seconds

This multicenter randomized controlled trial evaluated the long-term outcomes of immediate versus delayed intrauterine device (IUD) placement after second-trimester medical abortion in 179 women. At 12 months, IUD use was lower in the immediate placement group (51.6%) compared to the delayed group (69.2%, p=0.04), with a significantly higher expulsion rate of 36.4% versus 3.1% (p<0.001).

Key findings

  • IUD use at 12 months was 51.6% in the immediate group vs. 69.2% in the delayed group (p=0.04).
  • The expulsion rate was significantly higher in the immediate group at 36.4% compared to 3.1% in the delayed group (p<0.001).
  • Satisfaction with IUD use was high in both groups, at 88.3% overall.
  • Subsequent pregnancies occurred in 26.2% of the immediate group vs. 13.6% in the delayed group (p=0.08).

Why it matters

Understanding the implications of IUD placement timing after abortion is crucial for optimizing contraceptive strategies and patient satisfaction. This study highlights potential risks associated with immediate placement, which may influence clinical recommendations.

Source

PubMed · PMID 42266170Free full text on PubMed Central

Published in Acta Obstet Gynecol Scand. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Obstetrics & Gynecology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.